Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715466 | 0.87 | FASN (0.45) | FASNCAMKK2PDPK1PTGS2 | |
| Propionic Acid SCHEMBL4155344 | 0.85 | FASN (0.42) | FASNCAMKK2PDPK1PTGS2 | |
| Butyric Acid SCHEMBL4153848 | 0.84 | FASN (0.41) | FASNCAMKK2PDPK1PTGS2 | |
| 3-Methylbutanoic Acid SCHEMBL4163003 | 0.82 | FASN (0.40) | FASNCAMKK2PDPK1PTGS2 | |
| Propionic Acid SCHEMBL4155190 | 0.77 | PTGS2 (0.40) | BRD4PTGS2JAK2 | |
| SCHEMBL4166122 | 0.77 | MAPK10 (0.34) | BRD4MAPK10JAK3 | |
| SCHEMBL4160378 | 0.76 | NPC1 (0.42) | — | |
| SCHEMBL3243228 | 0.76 | CAMKK2 (0.36) | FASNCAMKK2DGAT2PDPK1JAK2 | |
| SCHEMBL3242761 | 0.75 | CAMKK2 (0.46) | FASNCAMKK2PDPK1PTGS2 | |
| SCHEMBL3250654 | 0.74 | PDPK1 (0.41) | VCPFASNCAMKK2DGAT2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | VCP 3103/4885FASN 2527/4885CNR1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.